title: A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has anti-tumor activity in hepatocellular carcinoma (HCC). A phase I/II study was performed in advanced HCC patients (pts).
  
  
  METHODS
  Thirty-three patients were enrolled. During Phase I, pts received 40 mg daily for 14 days q3 weeks; 2 of 5 patients developed DLT so dose was reduced to 20 mg/day. Twenty-eight patients received 20 mg/day.
  
  
  RESULTS
  No pt had a CR or PR, but 12 of 21 (57%) had SD. Two pts (9.5%) had late PR after discontinuing TAC-101. Median survival (MS) for all 28 pts treated with 20 mg/day was 12.7 months (95% CI 8.8-22.7); MS for 21 evaluable pts was 19.2 months (95% CI 10.4-27.6).
  
  
  CONCLUSIONS
  20 mg of TAC- was well tolerated. Significant disease stabilization (12/21 pts, 57%), 2 late PRs, and prolonged MS (19.2 months) suggest that TAC-101 provides meaningful patient benefit.
authors.affiliation: Department of Gastrointestinal Medical Oncology Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Kimberly B
authors.initials: KB
authors.lastname: Higginbotham
authors.forename: Richard
authors.initials: R
authors.lastname: Lozano
authors.forename: Thomas
authors.initials: T
authors.lastname: Brown
authors.forename: Yehuda Z
authors.initials: YZ
authors.lastname: Patt
authors.forename: Takashi
authors.initials: T
authors.lastname: Arima
authors.forename: James L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: Melanie B
authors.initials: MB
authors.lastname: Thomas
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001565:Benzoates / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D011379:Prognosis; D012176:Retinoids / Q000008:administration & dosage* / Q000493:pharmacokinetics; D015996:Survival Rate; D014018:Tissue Distribution; D014297:Trimethylsilyl Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D055815:Young Adult
chemical_list: D001565:Benzoates; D012176:Retinoids; C112689:TAC 101; D014297:Trimethylsilyl Compounds